Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma Bob Lanier, MD, Tracy Bridges,

Slides:

Advertisements

Similar presentations

Control of immunopathology during chikungunya virus infection Caroline Petitdemange, PhD, Nadia Wauquier, PhD, Vincent Vieillard, PhD Journal of Allergy.

Advertisements

D-dimer: A biomarker for antihistamine-resistant chronic urticaria

Comparative outcomes of leukotriene receptor antagonists and long-acting β-agonists as add-on therapy in asthmatic patients: A population-based study

Risk of an asthma exacerbation after bariatric surgery in adults

Treating acute rhinosinusitis: Comparing efficacy and safety of mometasone furoate nasal spray, amoxicillin, and placebo Eli O. Meltzer, MD, Claus Bachert,

Pharmacologic rationale for treating allergic and nonallergic rhinitis

Oral Phenylephrine HCl for Nasal Congestion in Seasonal Allergic Rhinitis: A Randomized, Open-label, Placebo-controlled Study Eli O. Meltzer, MD, Paul.

Fatty acids, inflammation, and asthma

Jessica P. Hollenbach, PhD, Michelle M. Cloutier, MD

The XTEND-CIU study: Long-term use of omalizumab in chronic idiopathic urticaria Marcus Maurer, MD, Allen Kaplan, MD, Karin Rosén, MD, PhD, Michael Holden,

Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD

Fluticasone furoate nasal spray: A single treatment option for the symptoms of seasonal allergic rhinitis Harold B. Kaiser, MD, Robert M. Naclerio, MD,

Probiotics in prevention of IgE-associated eczema: A double-blind, randomized, placebo-controlled trial Thomas R. Abrahamsson, MD, Ted Jakobsson, MD,

Shyam Joshi, MD, David A. Khan, MD

Is 9 more than 2 also in allergic airway inflammation?

Probiotics during the first 7 years of life: A cumulative risk reduction of eczema in a randomized, placebo-controlled trial Marko Kalliomäki, MD, PhD,

Fatty acids, inflammation, and asthma

Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy Allen Kaplan, MD, Dennis Ledford,

Inhaler reminders improve adherence with controller treatment in primary care patients with asthma Juliet M. Foster, PhD, Tim Usherwood, BSc, MD, BS,

Allergy immunotherapy among Medicaid-enrolled children with allergic rhinitis: Patterns of care, resource use, and costs Cheryl S. Hankin, PhD, Linda.

Omalizumab is effective in cold urticaria—results of a randomized placebo-controlled trial Martin Metz, MD, Andrea Schütz, MD, Karsten Weller, MD, Marina.

Randomized trial of the effect of drug presentation on asthma outcomes: The American Lung Association Asthma Clinical Research Centers Robert A. Wise,

Lieuwe D. Bos, MSc, PhD, Peter J. Sterk, MD, PhD, Stephen J

Clinical studies of the DP1 antagonist laropiprant in asthma and allergic rhinitis George Philip, MD, Janet van Adelsberg, MD, Thomas Loeys, PhD, Nancy.

Treatment of chronic autoimmune urticaria with omalizumab

A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine–refractory chronic idiopathic urticaria

Peter M. Wolfgram, MD, David B. Allen, MD

Asthma symptom re-emergence after omalizumab withdrawal correlates well with increasing IgE and decreasing pharmacokinetic concentrations Raymond G.

Successful management of mite-allergic asthma with modified extracts of Dermatophagoides pteronyssinus and Dermatophagoides farinae in a double-blind,

Jewlya Lynn, PhD, Sophie Oppenheimer, MS, MPH, Lorena Zimmer, MA

Debra J. Palmer, PhD, Thomas R. Sullivan, BMa&CompSc(Hons), Michael S

Phillip Lieberman, MD, Michael Tankersley, MD

High eosinophil count: A potential biomarker for assessing successful omalizumab treatment effects William Busse, MD, Sheldon Spector, MD, Karin Rosén,

Time for a paradigm shift in asthma treatment: From relieving bronchospasm to controlling systemic inflammation Leif Bjermer, MD Journal of Allergy.

What are the best outcome measurements for atopic eczema

Food allergy: A review and update on epidemiology, pathogenesis, diagnosis, prevention, and management Scott H. Sicherer, MD, Hugh A. Sampson, MD Journal.

Biosimilars and drug development in allergic and immunologic diseases

Daphne Koinis-Mitchell, PhD, Timothy Craig, DO, Cynthia A

A cluster-randomized trial shows telephone peer coaching for parents reduces children's asthma morbidity Jane M. Garbutt, MB, ChB, Yan Yan, MD, PhD,

Claus Bachert, MD, PhD, Cezmi A. Akdis, MD

What is an “eosinophilic phenotype” of asthma?

Medication use in children with asthma in Finland from 1995 to 2006

Sublingual immunotherapy with once-daily grass allergen tablets: A randomized controlled trial in seasonal allergic rhinoconjunctivitis Stephen R. Durham,

Treating acute rhinosinusitis: Comparing efficacy and safety of mometasone furoate nasal spray, amoxicillin, and placebo Eli O. Meltzer, MD, Claus Bachert,

H. William Kelly, PharmD Journal of Allergy and Clinical Immunology

Autophagy: Nobel Prize 2016 and allergy and asthma research

Food allergy: Epidemiology, pathogenesis, diagnosis, and treatment

Efficacy and safety of sublingual tablets of house dust mite allergen extracts in adults with allergic rhinitis Karl-Christian Bergmann, MD, Pascal Demoly,

Syk expression and IgE-mediated histamine release in basophils as biomarkers for predicting the clinical efficacy of omalizumab Donald W. MacGlashan,

Asthma control can be maintained when fluticasone propionate/salmeterol in a single inhaler is stepped down Eric D. Bateman, MD, Loretta Jacques, PhD,

Bruce G. Bender, PhD, Alex Pedan, PhD, Laleh T. Varasteh, RPh, MSF

Anaphylaxis during anesthesia in France: An 8-year national survey

Efficacy of nasal mometasone for the treatment of chronic sinonasal disease in patients with inadequately controlled asthma Anne E. Dixon, MA, BM BCh,

Efficacy and safety of sublingual tablets of house dust mite allergen extracts: Results of a dose-ranging study in an environmental exposure chamber

Efficacy and safety of the SQ house dust mite sublingual immunotherapy tablet in Japanese adults and adolescents with house dust mite–induced allergic.

Pınar Uysal, MD, Esben Eller, MSc, PhD, Charlotte G

Short course of systemic corticosteroids in sinonasal polyposis: A double-blind, randomized, placebo-controlled trial with evaluation of outcome measures

The Editors' Choice Journal of Allergy and Clinical Immunology

Macrolide antibiotics and asthma treatment

Statistical issues in clinical trials that involve the double-blind, placebo-controlled food challenge Vernon M. Chinchilli, PhD, Laura Fisher, MD, Timothy.

Asthma: The past, future, environment, and costs

Alan Menter, MD, Stephen K

Probiotic supplementation for the first 6 months of life fails to reduce the risk of atopic dermatitis and increases the risk of allergen sensitization.

Effect of omalizumab treatment on peripheral eosinophil and T-lymphocyte function in patients with allergic asthma Oliver Noga, MD, Gerald Hanf, MD,

Lisa A. Beck, MD, Sarbjit Saini, MD

The use of serum-specific IgE measurements for the diagnosis of peanut, tree nut, and seed allergy Jennifer M. Maloney, MD, Magnus Rudengren, BSc, Staffan.

Advances in pediatric asthma in 2007

Safety and efficacy of repeated monthly carboplatin desensitization

Natural history of cow’s milk allergy

Primary prevention of asthma and allergy

Presentation transcript:

Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma Bob Lanier, MD, Tracy Bridges, MD, Marek Kulus, MD, Angel Fowler Taylor, RPh, Indrias Berhane, PhD, Carlos Fernandez Vidaurre, MD Journal of Allergy and Clinical Immunology Volume 124, Issue 6, Pages 1210-1216 (December 2009) DOI: 10.1016/j.jaci.2009.09.021 Copyright © 2009 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 1 Patient disposition. ∗A patient could be excluded for more than 1 reason. ∗∗One patient subsequently received placebo but was not randomized to treatment; therefore, the patient was excluded from the intent-to-treat (ITT) population (n = 206) but included in the safety population (n = 207). Fifty-one patients were excluded from the modified ITT (mITT) population because of noncompliance with GCP study conduct issues (mITT population: omalizumab [n = 384], placebo [n = 192]). ∗∗∗The sponsors conducted site audits as part of the study monitoring procedures. Concerns were raised regarding the manner in which the trials were conducted and data collected for 3 sites in particular. As a result of the audit findings at 2 of the sites, all randomized patients were discontinued from study drug and the sites were closed, and efficacy data were excluded. The third site with less significant issues was closed to further enrollment, but all randomized patients were allowed to continue until they completed the trial. Sites were instructed to record the reason for withdrawal as “admin problems” when special circumstances occurred, such as study closure or cancellation, or when patients relocated and could no longer participate. Journal of Allergy and Clinical Immunology 2009 124, 1210-1216DOI: (10.1016/j.jaci.2009.09.021) Copyright © 2009 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 2 Clinically significant asthma exacerbation rates over a period of 24 weeks (primary outcome; A) and 52 weeks (B) in patients with moderate-to-severe asthma treated with add-on omalizumab (n = 384) or placebo (n = 192) to an optimized asthma program (mITT population). Journal of Allergy and Clinical Immunology 2009 124, 1210-1216DOI: (10.1016/j.jaci.2009.09.021) Copyright © 2009 American Academy of Allergy, Asthma & Immunology Terms and Conditions